<DOC>
	<DOCNO>NCT02354859</DOCNO>
	<brief_summary>The purpose study assess efficacy IV gallium improve pulmonary function measure 5 % great relative improvement force expiratory volume one second ( FEV1 ) baseline Day 28 . Funding Source - FDA OOPD</brief_summary>
	<brief_title>A Phase 2 IV Gallium Study Patients With Cystic Fibrosis ( IGNITE Study )</brief_title>
	<detailed_description>This phase 2 , multi-center , randomize , placebo-controlled trial adult CF chronically infect P. aeruginosa . The study evaluate safety clinical efficacy five day infusion IV gallium nitrate ( IV gallium ) . The purpose study assess efficacy IV gallium improve pulmonary function measure 5 % great relative improvement force expiratory volume one second ( FEV1 ) baseline Day 28 .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Gallium nitrate</mesh_term>
	<criteria>Greater equal 18 year age Screening Documented chronic colonization P. aeruginosa define dentification two sputum oropharyngeal culture within year prior Day 1 Documentation CF diagnosis evidence one clinical feature consistent CF phenotype one follow criterion : 1. sweat chloride ≥ 60 mEq/liter quantitative pilocarpine iontophoresis test ( QPIT ) 2. two wellcharacterized mutation cystic fibrosis transmembrane conductance regulator ( CFTR ) gene 3 . Abnormal nasal potential difference ( NPD ; change NPD response low chloride solution isoproteronol less 5 mV ) FEV1 ≥ 25 % predict value Screening Able expectorate sputum Serum liver function test ≤ 2.5 x upper limit normal Screening Serum urea nitrogen ( BUN ) ≤ 1.5 x upper limit normal Screening Serum creatinine ≤ 2.0 mg/dl ≤ 1.5 x upper limit normal Screening Hemoglobin ≥ 9 g/dl , platelet ≥ 100,000/mm3 , white blood cell ( WBC ) ≥ 4,500/mm3 Screening Ionized calcium ≥ low limit normal Screening Written inform consent obtain subject subject 's legal representative Able communicate Investigator comply requirement protocol If female childbearing potential , must negative pregnancy test Day 1 prior receive study drug If female childbearing potential , willing use adequate contraception duration study Visit 5 , determine investigator If male able father child , willing use adequate contraception duration study Visit 5 , determine investigator Clinically stable significant change health status within 14 day prior Day 1 Exclusion criterion : Use inhale antibiotic within seven day prior Day 1 Unable unwilling withhold use chronic inhale antibiotic Day 28 Use intravenous , inhaled , oral antibiotic acute indication within 14 day prior Day 1 Use bisphosphonates within seven day prior Day 1 History osteoporosis ( defined recent dexa scan Tscore ≤ 2.5 dexa scan perform within five year prior Screening ) Lactating female Known sensitivity gallium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Gallium Nitrate</keyword>
	<keyword>IV Gallium</keyword>
	<keyword>Pseudomonas aeruginosa</keyword>
</DOC>